Abbott Laboratories (ABT) Fair Value 2026

ABT · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.8 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-27, Abbott Laboratories (ABT) trades at $111.59, versus a $79.88 median fair value across its 11 active models — 28.4% below the current price. QOC: 8.8/10. Value Trap Risk: 0/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $108.56.

Key Facts

Ticker
ABT
Price
$111.59
Quality Score
8.8/10
Value Trap Risk
0/100
Models Active
11/13
Last Updated
Strength: First Chicago suggests +5.9% upside with 61% confidence
Risk: Majority of models suggest overvaluation

Is Abbott Laboratories (ABT) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Abbott Laboratories (ABT) appears overvalued as of : the median of 11 independent fair value estimates is $79.88, 28.4% below the current price of $111.59. Estimates range from $29.98 to $182.06. ABT scores 8.8/10 on fundamental quality and 0/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. ABT’s -28.4% gap is wider than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Abbott Laboratories Stock in 2026? →

What Fair Value Does Each Model Give ABT?

11 Intrinsic Value Models vs. Current Price ($111.59)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $108.56 -2.7%
Intrinsic · High Conviction
 $33.75 -69.8%
Ensemble · Medium Conviction
 $79.88 -28.4%
Scenario · High Conviction
 $118.17 +5.9%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is ABT's Fair Value Range?

Spread across 11 independent models · $29.98 to $182.06

CirclFi's 11 active models place Abbott Laboratories (ABT) between $29.98 and $182.06 per share, a spread of 190% of the median. The median of that range — $79.88 — is the fair value CirclFi publishes for ABT, against a current price of $111.59.

Low · ML-RIVHigh · Regime Cross
$29.98median $79.88$182.06
Where the range comes from
Most bearish modelML Residual Income$29.98
Most bullish modelRegime Cross-Sectional$182.06
Model agreement2 bullish · 8 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for ABT. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on ABT, not a CirclFi price target. How each model works →

What Is Abbott Laboratories (ABT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Abbott Laboratories at its current price of $111.59. The median intrinsic value is estimated at $79.88 (-28.4% vs price), with 8 models flagging overvaluation risk. Model dispersion is worth noting: Regime Cross targets $182.06 (+63.1%), versus ML-RIV at $29.98 (-73.1%). This +136.3% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About ABT?

11 of 13 models are currently active for ABT. Of these, 2 models suggest upside while 9 models suggest overvaluation. Taken together, their median fair value for ABT is $79.88 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $108.56 on its own, implying -2.7% downside from the current price. See which stocks rank higher →

How Does ABT Rank in Medical Devices?

Among 157 Medical Devices stocks, ABT ranks #12 by Quality of Company score. CirclFi's QOC score of 8.8/10 evaluates 32 fundamental signals. A score of 8.8 places ABT in the top tier.

See all Most Undervalued Medical Devices Stocks →

Within the Medical Devices space, Abbott Laboratories competes in an environment where R&D productivity ratio often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is ABT a Value Trap?

CirclFi's Value Trap algorithm assigns ABT a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Abbott Laboratories. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Abbott Laboratories's fundamental quality profile registers 8.8/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +136.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ABT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ABT's 11 active models, average confidence is 53%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Abbott Laboratories Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

PENPenumbra, Inc.QOC 8.9TCMDTactile Systems Technology, Inc.QOC 8.8BSXBoston Scientific CorporationQOC 8.9ESMCEscalon Medical Corp.QOC 8.7INSPInspire Medical Systems, Inc.QOC 9.0EWEdwards Lifesciences CorporationQOC 8.7PRCTPROCEPT BioRobotics CorporationQOC 6.9VYCOVycor Medical, Inc.QOC 6.0ALURAllurion Technologies Inc.QOC 4.8IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: PEN · TCMD · BSX · ESMC · INSP · EW · PRCT · VYCO · ALUR · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to ABT?

7 companies across all industries closest to ABT’s Quality of Company score of 8.8/10.

HWKNHawkins, Inc.QOC 8.8PEverpure, Inc.QOC 8.8HOGHarley-Davidson, Inc.QOC 8.8INGRIngredion IncorporatedQOC 8.8UALUnited Airlines Holdings, Inc.QOC 8.8SNPSSynopsys, Inc.QOC 8.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: HWKN · P · HOG · INGR · UAL · SNPS · NVDA

Where Does ABT Sit in CirclFi's Medical Devices Rankings?

ABT is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Abbott Laboratories’s Valuation?

What is Abbott Laboratories's intrinsic value in 2026?

CirclFi puts Abbott Laboratories (ABT)'s intrinsic value at $79.88 — the median of 11 independent model estimates as of 2026-08-27, ranging from $29.98 to $182.06. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $108.56 on its own. The Quality of Company score is 8.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ABT overvalued or undervalued right now?

At $111.59, 2 of 11 active models suggest ABT may be undervalued, while 9 indicate potential overvaluation. The median of all 11 fair value estimates is $79.88, 28.4% below the current price of $111.59 — a consensus view that ABT is overvalued. The assessment depends on which methodology best fits Abbott Laboratories's business model in Medical Devices.

What does a Quality of Company score of 8.8 mean for ABT?

Abbott Laboratories's QOC of 8.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on ABT?

CirclFi analyzes ABT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ABT?

Of the 11 models currently active on ABT, Regime Cross-Sectional is the most bullish at $182.06 per share, and ML Residual Income is the most bearish at $29.98. CirclFi's published fair value for ABT is the median of that range, $79.88, not either extreme. The gap between the two ends equals 190% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is ABT a value trap in 2026?

Abbott Laboratories's Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Abbott Laboratories (ABT) has a median fair value of $79.88 — 28.4% below the current price of $111.59 — as of 2026-08-27.” Source: circlfi.com/stock/ABT/ · Methodology
Primary sources for this ABT valuation
  • Financial statements: Abbott Laboratories 10-K and 10-Q filings on SEC EDGAR (CIK 0000001800) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ABT as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on ABT.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for ABT Unlock All 11 — $39/mo